Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis. (July 2019)

• Record Type: Journal Article
• Authors: Gaye, Elisabeth; Geier, Margaux; Bore, Paul; Guilloïque, Marine; Lucia, Francois; Quéré, Gilles; Gouva, Sylvie; Robinet, Gilles; Descourt, Renaud
• Is Part Of: Lung cancer. Volume 133(2019)
• Page Start: 1
• Page End: 3
• Publication Date: 2019-07
• Subjects: Leptomeningeal carcinomatosis -- Brigatinib -- Tyrosine kinase inhibitor -- NSCLC; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2019.04.013
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Leptomeningeal disease (LMD) in lung cancer is associated to poor prognosis. ALK-TKi brigatinib has increased intracranial activity then other ALK TKIs. Data on brigatinib efficacy on LMD is lacking. Case showing prolonged (>14 months) intra-cranial response to brigatinib. Intra-cranial efficiency of brigatinib over crizotinib- and ceretinib- resistance. Abstract: Objectives: Brigatinib is a second-generation ALK inhibitor which demonstrated activity over crizotinib-resistance, especially on brain metastasis by increased blood-brain penetration. However, its activity on lepto-meningeal disease is unknown and scarcely reported. Materials and methods: We hereby report the case of lepto-meningeal disease in crizotinib- and ceretinib- treated patient who was successfully treated by brigatinib. Results: The patient achieved intracranial response to brigatinib more than 14 months. Conclusion: Our case provides additional data on brigatinib's intracranial activity, not only on brain metastasis but also on leptomeningeal disease, after experiencing resistance to both crizotinib and ceretinib, 1 st and 2 nd generation ALK inhibitors.